TrialJournal of opioid management

Formulation development and a Phase 1 clinical study of PF614-MPAR, an oxycodone prodrug with oral opioid overdose protection.

D Lynn Kirkpatrick et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.